Source: Facebook
Market Herald logo

Find out more about this capital raise

Be the first with the news that moves the market
  • NervGen Pharma (NGEN) has announced a non-brokered private placement for gross proceeds of US$15,225,000
  • The company will issue 10,150,000 units priced at $1.50 per unit
  • Net proceeds will be used to fund continued development of their lead drug candidate, NVG-291
  • The placement is expected to close on or about July 8, 2022
  • NervGen is a biotech company dedicated to creating treatments for nerve damage and neurodegenerative diseases
  • NervGen Pharma Corp. (NGEN) opened trading at C$1.94

NervGen Pharma (NGEN) has announced a non-brokered private placement for gross proceeds of US$15,225,000.

The company will issue 10,150,000 units priced at $1.50 per unit.

Each unit will consist of one common share and one-half of one common share purchase warrant. Each whole warrant will be exercisable for one additional share for US$1.75 for 60 months.

All securities issued will be subject to a four month hold period.

Net proceeds will be used to fund continued development of their lead drug candidate, NVG-291, and for general corporate purposes.

The placement is expected to close on or about July 8, 2022 and is subject to the receipt of all necessary stock exchange approvals, including the approval of the TSXV.

NervGen is a biotech company dedicated to creating treatments for nerve damage and neurodegenerative diseases.

NervGen Pharma Corp. (NGEN) opened trading at C$1.94.

More From The Market Herald
Small Pharma - CEO, George Tziras.

" Small Pharma (TSXV:DMT) announces NCIB

Small Pharma (DMT) has received TSXV approval for a normal course issuer bid.
High Tide - CEO, Raj Grover.

" High Tide (TSXV:HITI) secures commitment for $19M credit facility

High Tide (HITI) has signed a binding commitment letter with Connect First Credit Union.
Spectral Medical Inc. - CMO, Dr. John Kellum

" Spectral (TSX:EDT) gets FDA approval for Tigris trial

Spectral Medical (EDT) announced that the U.S. Food and Drug Administration (FDA) has approved ten new clinical trial sites for the Tigris trial.

" Diagnos (TSXV:ADK) receives approval for its AI enabled Pathology Detection Systems

Diagnos (ADK) has received approval from the Costa Rican regulatory agency for its Artificial Intelligence (AI) enabled Pathology Detection Systems.